まとめ
重症患者は,集中治療室 (ICU) に入院した最初の1週間以内に,骨格筋の急速な衰えを経験します. 多臓器不全の患者では,筋肉の喪失がより深刻であり,標的を絞った介入の必要性を強調しています.
科学分野:
- クリティカルケア医療は,重症治療薬です.
- 筋肉の生理学について
- 集中治療室 (ICU) のアウトカムについて
背景:
- 深刻な病気の生存者は,しばしば重要な骨格筋の消耗を経験し,機能障害につながります.
- タンパク質の合成と分解を含む筋肉喪失のメカニズムを理解することは,患者の回復を改善するために不可欠です.
研究 の 目的:
- 重症患者の骨格筋の衰えを将来的に特徴づけるために.
- 筋肉消耗の病原性における変異したタンパク質合成と分解の役割を定義する.
主な方法:
- ICU入院後24時間以内に63人の重症患者の募集を予定しています.
- 1日,3日,7日,10日,直体横断面 (CSA) の連続超音波測定を行った.
- 筋肉繊維CSAの定量化,タンパク質とDNAの比率,およびタンパク質合成と分解率の評価.
主要な成果:
- 10日目には直骨筋CSAを17.7%大幅に減少させました.
- マルチ臓器不全の患者では,単一の臓器不全と比較して,筋肉の消耗がより顕著でした.
- 筋肉のタンパク質合成は早期に抑制され,タンパク質の分解は研究を通して上昇し続けました.
結論:
- 骨格筋の衰弱は,重篤な病気の最初の週に早く,急速に起こります.
- 筋肉の衰弱の重さは,多臓器不全の存在と相関しています.
- 研究結果は,重篤な疾患における筋肉の衰弱の病理生理学についての洞察を提供します.
関連する概念動画
Disorders of the Skeletal Muscle
2.3K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.3K
Skeletal Muscle Relaxants: Adverse Effects
1.2K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
1.2K
Skeletal Muscle Relaxants: Therapeutic Uses
1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Cross-bridge Cycle
108.9K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
108.9K
Myasthenia Gravis: Diagnostic Tests
3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K


